genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2015
Mundipharma Deutschland GmbH & Co. KG
News
Sigma-Aldrich Says Currency, M&A Costs Reduce Q4 Profits
Cancer
Infinity Regains Rights to PI3K and FAAH Programs
Cancer
Mundipharma Commits $50M to Infinity’s PI3K Inhibitor Program in 2013
Cancer
Allos Therapeutics Gets $50M Up Front in Deal with Mundipharma for Cancer Drug Folotyn
News
Mundipharma Successfully Completes European Late-Stage Program for SkyePharma’s Asthma Treatment
News
Stemgent Licenses TET’s Stem Cell Reprogramming Reagents
News
Purdue Pharma Makes $75M Equity Investment in Infinity
Scroll Up
Scroll Up
